Home - Sponsored - AZ See Beyond Sugar Hub

This is a promotional web page developed and funded by AstraZeneca for UK healthcare professionals only.

See beyond sugar home

The FORXIGA® (Dapagliflozin) prescribing information is available via the tabs throughout the site. Adverse event reporting information can be found at the bottom of this page.

Based on published evidence of positive cardiovascular (CV) outcome trials in type 2 diabetes (T2D), the updated NICE NG28 guideline for T2D now recommends that CV risk should be integral to T2D management, determining the choice of glycaemic treatment.¹ The primary focus of T2D care was previously about achieving optimal glycaemic control. CV risk was managed separately in parallel through blood pressure, lipid and lifestyle modification.²

Explore the See Beyond Sugar website to build your knowledge of the latest NICE NG28 T2D guideline updates using a series of CPD-certified educational materials developed to support your clinical practice.

Review the CPD-certified Cardiorenal Protection module to learn more about the NICE guideline NG28 updates

Use the NICE NG28 implementation support infographic to assist you in applying the guideline to your clinical practice

Quickly, navigate to key sections of the NICE NG28 guideline, by using the interactive NG28 guideline explorer

Two clinical experts discuss the updated NICE T2D guideline and how they apply it to their clinical practice

Learn more about the patient perspective by following Ian’s journey

Test your knowledge of the updated NICE type 2 diabetes treatment recommendations on the management of cardiovascular risk.

Earn a CPD certificate upon successful completion of this brief e-learning module

FORXIGA® (dapagliflozin) | Therapeutic indication

Type 2 diabetes mellitus

FORXIGA is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance. In addition to other medicinal products for the treatment of type 2 diabetes.

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the summary of product characteristics.

Heart failure

FORXIGA is indicated in adults for the treatment of symptomatic chronic heart failure.

Chronic kidney disease

FORXIGA is indicated in adults for the treatment of chronic kidney disease.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.

References

1. ©NICE [2022] Type 2 diabetes in adults: management. Available from https://www.nice.org.uk/guidance/ng28 All rights reserved.
Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

2. NICE Type 2 diabetes in adults: management (NG28). Published December 2015; updated November 2021.